// Medical Decision Tree
digraph {
	rankdir=TB size="8,8"
	root [label="Advanced Prostate Cancer\n\nThis node is for patients with advanced prostate cancer. The outcomes include better evidence could change confidence and balance between benefits and risks/burdens unclear."]
	root -> "Better evidence" [label="Better evidence could change confidence"]
	root -> "Balance between Benefits & Risks/Burdens unclear" [label="Balance between Benefits & Risks/Burdens unclear"]
	"Better evidence" [label="Body of evidence strength\n\nGrade A indicates that benefits and risks/burdens are balanced, best action depends on patient circumstances, and future research is unlikely to change confidence. Grade B indicates that benefits and risks/burdens are balanced, best action depends on patient circumstances, and better evidence could change confidence. Grade C indicates uncertainty regarding the balance between benefits and risks/burdens, alternative strategies may be equally reasonable, and better evidence could change confidence."]
	"Better evidence" -> A1 [label="Grade A"]
	"Better evidence" -> B1 [label="Grade B"]
	"Better evidence" -> C1 [label="Grade C"]
	"Balance between Benefits & Risks/Burdens unclear" [label="Balance between Benefits & Risks/Burdens\n\nUnclear balance between benefits and risks/burdens, with net benefit/harm being comparable to other options."]
	"Balance between Benefits & Risks/Burdens unclear" -> "Conditional Recommendation" [label="Net benefit (or net harm) comparable to other options"]
	"Balance between Benefits & Risks/Burdens unclear" -> "Conditional Recommendation" [label="Alternative strategies may be necessary"]
	A1 [label="Evidence strength\n\nThe AUA categorize the body of evidence strength as Grade A, B, or C. Grade A is considered to be well-conducted and highly-generalizable RCTs or exceptionally strong observational studies with consistent findings. Grade B is considered to be RCTs with some weaknesses of procedure or generalizability or moderately strong observational studies with consistent findings. Grade C is considered to be RCTs with serious deficiencies of procedure or generalizability or extremely small sample sizes or observational studies that are inconsistent, have small sample sizes, or have other problems that potentially confound interpretation of data."]
	A1 -> "AUA categorize as Grade A" [label=A]
	A1 -> "AUA categorize as Grade B" [label=B]
	A1 -> "AUA categorize as Grade C" [label=C]
	B1 [label="Altered genes with a role in homologous recombination repair\n\nPatients with advanced prostate cancer who have a qualifying alteration in pre-specified genes with a direct or indirect role in homologous recombination repair. Cohort A includes alterations in BRCA1, BRCA2, or ATM, while cohort B includes alterations in any of the 12 other pre-specified genes."]
	B1 -> "Node for treatment with physician's choice of enzalutamide or biraterone acetate" [label="Cohort A - at least 1 alteration in BRCA1, BRCA2, or ATM"]
	B1 -> "Node for further evaluation and potential treatment options" [label="Cohort B - alterations in any of 12 other pre-specified genes"]
	C1 [label="Grade of body of evidence strength\n\nMedical recommendations are divided into three categories based on the strength of evidence to support them: Strong or Moderate, Conditional, and Uncertainty. The stronger the evidence, the more likely it is that the statement can be applied to most patients and circumstances. However, even when evidence is weaker, conditional recommendations can still be supported. When evidence is uncertain, alternative strategies may be equally reasonable."]
	C1 -> "Node for application of statement to most patients" [label="Strong or Moderate Recommendation"]
	C1 -> "Node for support by any evidence strength" [label="Conditional Recommendation"]
	C1 -> "Node for alternative strategies" [label="Uncertainty regarding balance"]
	"Conditional Recommendation" [label="Presence of pre-existing conditions\n\nThis node checks if the patient has any pre-existing conditions and provides three possible outcomes based on the strength of evidence. Conditional recommendations are used when the balance between benefits and risks/burden is unclear. Non-directive statements are used when there is no apparent net benefit or harm. Strong or Moderate Recommendations can be applied to most patients in most circumstances and have a high level of confidence."]
	"Conditional Recommendation" -> A [label="Conditional recommendation"]
	"Conditional Recommendation" -> B [label="Non-directive statement"]
	"Conditional Recommendation" -> C [label="Strong or Moderate Recommendation"]
	"AUA categorize as Grade A" [label="Prostate cancer\n\nBased on the AUA's grading system, the strength of evidence for prostate cancer diagnosis is classified as Grade A, B, or C. Grade A indicates well-conducted and highly generalizable RCTs or strong observational studies with consistent findings. Grade B indicates RCTs with some weaknesses or moderately strong observational studies with consistent findings. Grade C indicates RCTs with serious deficiencies or extremely small sample sizes, or inconsistent observational studies. This node will determine the risk level of the patient's prostate cancer based on the grading system."]
	"AUA categorize as Grade A" -> node1 [label="Low-risk prostate cancer"]
	"AUA categorize as Grade A" -> node2 [label="Intermediate-risk prostate cancer"]
	"AUA categorize as Grade A" -> node3 [label="High-risk prostate cancer"]
	"AUA categorize as Grade B" [label="AUA categorizes strength of evidence as Grade A, B, or C\n\nThe AUA categorizes the strength of evidence based on the quality and generalizability of the studies. Grade A evidence is considered the strongest and most reliable, while Grade C evidence may have limitations that could affect the interpretation of data. It is important to consider the level of evidence when making a diagnosis."]
	"AUA categorize as Grade B" -> "Node #1" [label="Grade A evidence"]
	"AUA categorize as Grade B" -> "Node #2" [label="Grade B evidence"]
	"AUA categorize as Grade B" -> "Node #3" [label="Grade C evidence"]
	"AUA categorize as Grade C" [label="Body of evidence strength\n\nBody of evidence strength as defined by the AUA categorization"]
	"AUA categorize as Grade C" -> "Node for well-conducted and highly-generalizable RCTs or exceptionally strong observational studies with consistent findings" [label="Grade A"]
	"AUA categorize as Grade C" -> "Node for RCTs with some weaknesses of procedure or generalizability or moderately strong observational studies with consistent findings" [label="Grade B"]
	"AUA categorize as Grade C" -> "Node for RCTs with serious deficiencies of procedure or generalizability or extremely small sample sizes or observational studies that are inconsistent, have small sample sizes, or have other problems that potentially confound interpretation of data" [label="Grade C"]
	"Node for treatment with physician's choice of enzalutamide or biraterone acetate" [label="Previous use of enzalutamide and abiraterone acetate\n\nNineteen percent of patients received both enzalutamide and abiraterone acetate, and the remaining 81% received one of the two. All patients had a qualifying alteration in pre-specified genes with a direct or indirect role in homologous recombination repair."]
	"Node for treatment with physician's choice of enzalutamide or biraterone acetate" -> "cohort A or cohort B" [label="Choice of enzalutamide or biraterone acetate"]
	"Node for support by any evidence strength" [label="Uncertainty regarding balance between benefits and risks\n\nWhen body of evidence strength Grade C is used, there is uncertainty regarding the balance between benefits and risks/burdens; therefore, alternative strategies may be equally reasonable."]
	"Node for support by any evidence strength" -> "Unique identifier for the next node" [label="Alternative strategies may be equally reasonable"]
	"Node for alternative strategies" [label="Balance between Benefits & Risks/Burdens unclear\n\nBased on the medical information, there is uncertainty regarding the balance between benefits and risks/burdens for the patient. Further evaluation is needed to determine if the net benefit or harm is comparable to other options. Alternative strategies may also be considered."]
	"Node for alternative strategies" -> node1 [label="Net benefit (or net harm) comparable to other options"]
	"Node for alternative strategies" -> node2 [label="Alternative strategies may be equally reasonable"]
	A [label="Evidence strength\n\nThe AUA categorizes evidence strength as Grade A, B, or C based on the quality and generalizability of RCTs and observational studies. Grade A is the highest level and indicates well-conducted and highly-generalizable studies, while Grade C is the lowest level and indicates studies with serious deficiencies or small sample sizes."]
	A -> "Node for high evidence strength" [label="Grade A"]
	A -> "Node for moderate evidence strength" [label="Grade B"]
	A -> "Node for low evidence strength" [label="Grade C"]
	B [label="Evidence strength\n\nThe evidence strength of the medical information is categorized by the AUA into Grade A, B, or C. Grade A indicates well-conducted and highly-generalizable RCTs or exceptionally strong observational studies with consistent findings. Grade B indicates RCTs with some weaknesses of procedure or generalizability or moderately strong observational studies with consistent findings. Grade C indicates RCTs with serious deficiencies of procedure or generalizability or extremely small sample sizes or observational studies that are inconsistent, have small sample sizes, or have other problems that potentially confound interpretation of data."]
	B -> "Node for diagnosis of patient" [label="Grade A"]
	B -> "Node for diagnosis of patient" [label="Grade B"]
	B -> "Node for diagnosis of patient" [label="Grade C"]
	C [label="Patient circumstances\n\nBody of evidence strength Grade C in support of a Strong or Moderate Recommendation indicates that the statement can be applied to most patients in most circumstances but that better evidence is likely to change confidence. Conditional Recommendations also can be supported by any evidence strength."]
	C -> "Node for Grade A evidence strength" [label="Recommendation for most patients"]
	C -> "Node for Grade C evidence strength" [label="Uncertainty regarding balance of benefits and risks/burdens"]
	node1 [label="Suspicion of advanced prostate cancer and no prior histologic confirmation\n\nIn patients with suspicion of advanced prostate cancer and no prior histologic confirmation, clinicians should obtain tissue diagnosis from the primary tumor or site of metastases when clinically feasible. This is important for accurately diagnosing and treating the cancer, as subsequent treatment may depend on histologic and molecular features of the malignancy."]
	node1 -> 1 [label="Obtain tissue diagnosis from primary tumor or site of metastases"]
	node2 [label="Detection of metastatic lesions\n\nAdvanced imaging tests may enhance detection of metastatic lesions, but the impact on patients and OS has yet to be fully demonstrated. It is still unclear what may be gained by the early detection of recurrent disease. In instances of planned salvage radiation therapy or salvage lymphadenectomy, the treatment templates may be adjusted as a result of novel imaging findings. In addition, oligometastatic disease may be identified, and such patients may be offered enrollment in clinical trials. While such approaches may be intuitively appealing, to date there is a limited amount of evidence suggesting benefit in terms of a delay in disease progression (ORIOLE) or improvement in OS (SABR-COMET). There is still limited evidence that metastasis-directed therapy (MDT) confers a survival benefit."]
	node2 -> "Node 2" [label="Enhanced detection of metastatic lesions"]
	node3 [label="Suspicion of advanced prostate cancer\n\nIn patients with suspicion of advanced prostate cancer and no prior histologic confirmation, clinicians should obtain tissue diagnosis from the primary tumor or site of metastases when clinically feasible. Patients with clinical signs and symptoms suggestive of advanced prostate cancer should undergo a biopsy to obtain histologic confirmation at the time of diagnosis and at later dates, if needed. While biopsy of the metastatic deposit may be optimal, biopsy of the primary tumor may be all that is available. Although the clinical picture is often consistent with the diagnosis, subsequent treatment may strongly depend on histologic and molecular features of the malignancy."]
	node3 -> "Node 2" [label="Obtain tissue diagnosis from primary tumor or site of metastases"]
	"Node #1" [label="Presence of DNA repair gene aberrations\n\nThe presence of DNA repair gene aberrations can be an indicator of an increased risk for developing prostate cancer. This information can be obtained through genetic testing. If the result is positive, further testing and treatment options should be considered. If the result is negative, other potential causes for the patient's symptoms should be explored."]
	"Node #1" -> "Node 1" [label="Positive result"]
	"Node #1" -> "Node 2" [label="Negative result"]
	"Node #2" [label="Presence of DNA repair gene aberrations\n\nDNA repair gene aberrations are mutations in genes responsible for repairing damaged DNA. These mutations have been linked to increased risk of developing certain types of cancer and may impact treatment options. In this case, the presence of DNA repair gene aberrations may make a patient eligible for olaparib treatment, a targeted therapy for metastatic castration-resistant prostate cancer. It is important to consider this factor when determining the best course of treatment for the patient."]
	"Node #2" -> "Node identifying olaparib treatment" [label="Patient eligible for olaparib treatment"]
	"Node #2" -> "Node identifying alternative treatment options" [label="Patient not eligible for olaparib treatment"]
	"Node #3" [label="Presence of DNA repair gene aberrations\n\nThis condition indicates a potential diagnosis of metastatic castration-resistant prostate cancer. A positive result may lead to further testing and potential treatment with Olaparib, as seen in the TOPARP-B trial. Pre-existing conditions such as previous cancer diagnoses should be considered."]
	"Node #3" -> "Node 1" [label="Positive for DNA repair gene aberrations"]
	"Node #3" -> "Node 2" [label="Negative for DNA repair gene aberrations"]
	"Node for well-conducted and highly-generalizable RCTs or exceptionally strong observational studies with consistent findings" [label="Body of evidence strength\n\nThe strength of evidence is categorized by the AUA as Grade A, B, or C. Grade A evidence is considered to be the strongest, with well-conducted and highly-generalizable RCTs or exceptionally strong observational studies with consistent findings. Grade B evidence is considered to be moderately strong, with RCTs with some weaknesses of procedure or generalizability or moderately strong observational studies with consistent findings. Grade C evidence is considered to be the weakest, with RCTs with serious deficiencies of procedure or generalizability or extremely small sample sizes or observational studies that are inconsistent, have small sample sizes, or have other problems that potentially confound interpretation of data."]
	"Node for well-conducted and highly-generalizable RCTs or exceptionally strong observational studies with consistent findings" -> "Node for Grade A evidence" [label="Grade A evidence"]
	"Node for well-conducted and highly-generalizable RCTs or exceptionally strong observational studies with consistent findings" -> "Node for Grade B evidence" [label="Grade B evidence"]
	"Node for well-conducted and highly-generalizable RCTs or exceptionally strong observational studies with consistent findings" -> "Node for Grade C evidence" [label="Grade C evidence"]
	"Node for RCTs with some weaknesses of procedure or generalizability or moderately strong observational studies with consistent findings" [label="Evidence strength\n\nThe AUA categorizes evidence strength as Grade A, B, or C. Grade A evidence is the strongest, followed by Grade B and Grade C."]
	"Node for RCTs with some weaknesses of procedure or generalizability or moderately strong observational studies with consistent findings" -> "Unique identifier for the next node" [label="Grade A"]
	"Node for RCTs with some weaknesses of procedure or generalizability or moderately strong observational studies with consistent findings" -> "Unique identifier for the next node" [label="Grade B"]
	"Node for RCTs with some weaknesses of procedure or generalizability or moderately strong observational studies with consistent findings" -> "Unique identifier for the next node" [label="Grade C"]
	"Node for RCTs with serious deficiencies of procedure or generalizability or extremely small sample sizes or observational studies that are inconsistent, have small sample sizes, or have other problems that potentially confound interpretation of data" [label="Advanced Prostate Cancer\n\nThis node represents a check for advanced prostate cancer in a patient. The possible outcomes are based on the risk of bias in the medical study, with a high risk indicating a more severe form of cancer and a medium risk indicating a less severe form."]
	"Node for RCTs with serious deficiencies of procedure or generalizability or extremely small sample sizes or observational studies that are inconsistent, have small sample sizes, or have other problems that potentially confound interpretation of data" -> node_1 [label="High risk of bias"]
	"Node for RCTs with serious deficiencies of procedure or generalizability or extremely small sample sizes or observational studies that are inconsistent, have small sample sizes, or have other problems that potentially confound interpretation of data" -> node_2 [label="Medium risk of bias"]
	"cohort A or cohort B" [label="Prognostic factors\n\nEvaluation of prognostic factors using primary studies and systematic reviews that reported hazard ratios or the area under the receiver operating characteristic curve. Non-randomized studies of interventions, case reports, narrative reviews, case-control studies, non-English language articles, in vitro, and animal studies are excluded. Articles published in peer-reviewed journals in or after 1998 are included. Studies published prior to 1998 identified from reference lists are also included. Two investigators independently review titles and abstracts of all citations using a two-phase method for screening full-text articles identified during review of titles and abstracts."]
	"cohort A or cohort B" -> "Unique identifier for the next node" [label="Hazard ratios or area under the receiver operating characteristic curve"]
	"Unique identifier for the next node" [label="Elevated PSA levels\n\nPSA levels are often used as a marker for prostate cancer recurrence. If PSA levels are elevated, a PSMA PET-CT scan can be performed to help localize any recurrent cancer."]
	"Unique identifier for the next node" -> node_1 [label="Positive PSMA PET-CT scan"]
	"Unique identifier for the next node" -> node_2 [label="Negative PSMA PET-CT scan"]
	"Node for high evidence strength" [label="Patient circumstances\n\nWhen body of evidence strength is Grade A, the statement indicates that benefits and risks/burdens appear balanced, the best action depends on patient circumstances, and future research is unlikely to change confidence. When body of evidence strength Grade B is used, benefits and risks/burdens appear balanced, the best action also depends on individual patient circumstances and better evidence could change confidence. When body of evidence strength Grade C is used, there is uncertainty regarding the balance between benefits and risks/burdens; therefore, alternative strategies may be equally reasonable, and better evidence could change confidence."]
	"Node for high evidence strength" -> A [label="Strong or Moderate Recommendation"]
	"Node for high evidence strength" -> A [label="Conditional Recommendation"]
	"Node for high evidence strength" -> B [label="Benefits and risks/burdens appear balanced"]
	"Node for high evidence strength" -> C [label="Uncertainty regarding balance between benefits and risks/burdens"]
	"Node for moderate evidence strength" [label="Presence of pre-existing conditions\n\nWhen evaluating a patient for a potential diagnosis or treatment, it is important to consider any pre-existing conditions that may impact the benefits or harms of the recommended course of action. Depending on the strength of the supporting evidence, a conditional or strong/moderate recommendation may be given. A conditional recommendation indicates that the benefits and harms are finely balanced, while a strong/moderate recommendation indicates that the evidence supports clear benefits and risks. Future research may change the confidence in the recommendation. Grade A indicates the statement can be applied to most patients and future research is unlikely to change confidence, while Grade B indicates better evidence could change confidence and Grade C indicates that better evidence is needed to support the recommendation."]
	"Node for moderate evidence strength" -> node_2 [label="Conditional recommendation - consider benefits and harms"]
	"Node for moderate evidence strength" -> node_3 [label="Strong or moderate recommendation - direct patient to treatment"]
	"Node for low evidence strength" [label="Symptoms of advanced prostate cancer\n\nIf a patient is experiencing symptoms of advanced prostate cancer, a prostate biopsy should be performed to confirm the diagnosis."]
	"Node for low evidence strength" -> "Unique identifier for the next node" [label="Prostate biopsy"]
	"Node for diagnosis of patient" [label="Suspicion of advanced prostate cancer\n\nIn patients with suspicion of advanced prostate cancer and no prior histologic confirmation, clinicians should obtain tissue diagnosis from the primary tumor or site of metastases when clinically feasible. Patients with clinical signs and symptoms suggestive of advanced prostate cancer should undergo a biopsy to obtain histologic confirmation at the time of diagnosis and at later dates, if needed. While biopsy of the metastatic deposit may be optimal, biopsy of the primary tumor may be all that is available. Although the clinical picture is often consistent with the diagnosis, subsequent treatment may strongly depend on histologic and molecular features of the malignancy. For example, poly (ADP-ribose)."]
	"Node for diagnosis of patient" -> "Node ID":" Tissue Diagnosis" [label="Obtain tissue diagnosis from primary tumor or site of metastases"]
	"Node for Grade A evidence strength" [label="Evidence grade\n\nThe AUA categorizes evidence strength as Grade A, B, or C. Grade A evidence indicates strong and consistent findings from well-conducted studies, while Grade B and C evidence have some weaknesses or inconsistencies that may affect interpretation of data."]
	"Node for Grade A evidence strength" -> "Unique identifier for next node" [label="Advanced prostate cancer"]
	"Node for Grade C evidence strength" [label="Body of evidence strength\n\nBody of evidence strength is used to indicate the confidence in a recommendation or statement. Grades A, B, and C have different implications for patient care and potential changes in confidence."]
	"Node for Grade C evidence strength" -> "Node A" [label="Grade A"]
	"Node for Grade C evidence strength" -> "Node B" [label="Grade B"]
	"Node for Grade C evidence strength" -> "Node C" [label="Grade C"]
	1 [label="PSA level\n\nThe PSA level is an important biomarker for prostate cancer. A high PSA level may indicate the presence of prostate cancer, while a normal PSA level may indicate the absence of prostate cancer. Other factors such as age, race, and prior treatments should also be considered when interpreting the PSA level."]
	1 -> "Node #1" [label="High PSA level"]
	1 -> "Node #2" [label="Normal PSA level"]
	"Node 2" [label="Presence of DNA repair gene aberrations\n\nIn the TOPARP-B trial, Olaparib was found to be effective in treating metastatic castration-resistant prostate cancer with DNA repair gene aberrations. Therefore, the presence of these aberrations may indicate a potential treatment option."]
	"Node 2" -> "Node 1" [label="Positive for DNA repair gene aberrations"]
	"Node 2" -> "Node 2" [label="Negative for DNA repair gene aberrations"]
	"Node 1" [label="DNA repair gene aberrations\n\nTesting for DNA repair gene aberrations is an important step in diagnosing metastatic castration-resistant prostate cancer. Patients who test positive for these gene aberrations may benefit from treatment with olaparib, as shown in the TOPARP-B trial. This information can also be used to identify potential underlying mutational processes in the cancer, as seen in the Alexandrov et al. study."]
	"Node 1" -> node_1 [label="Positive for gene aberration"]
	"Node 1" -> node_2 [label="Negative for gene aberration"]
	"Node identifying alternative treatment options" [label="Patient eligibility for clinical trial\n\nClinical trials are listed by diagnosis and stage on the Clinicaltrials.gov website. In appropriate patients, clinical trial options should be considered, and trial options should be discussed with patients as part of the shared decision-making process. All clinical trials include specified aim(s) with a predetermined statistical plan. Institutional Review Boards approve all clinical trials and patient consent forms, and all patients must sign consent for trial participation."]
	"Node identifying alternative treatment options" -> "Clinical trial options node" [label="Eligible for clinical trial"]
	"Node identifying alternative treatment options" -> "Treatment options node" [label="Not eligible for clinical trial"]
	"Node for Grade A evidence" [label="Evidence strength\n\nAUA categorize s body of evidence strength as Grade A, B, or C. By definition, Grade A evidence is evidence about which the Panel has a high level of confidence in the estimate of effect."]
	"Node for Grade A evidence" -> "Advanced Prostate Cancer Node" [label="Grade A"]
	"Node for Grade A evidence" -> "Advanced Prostate Cancer Node" [label="Grade B"]
	"Node for Grade A evidence" -> "Advanced Prostate Cancer Node" [label="Grade C"]
	"Node for Grade B evidence" [label="Body of evidence strength\n\nBody of evidence strength can be used to determine the confidence in a recommendation for a patient diagnosis. Grade A indicates a balanced benefit and risk, Grade B indicates some uncertainty, and Grade C indicates significant uncertainty."]
	"Node for Grade B evidence" -> node_1 [label="Grade A"]
	"Node for Grade B evidence" -> node_2 [label="Grade B"]
	"Node for Grade B evidence" -> node_3 [label="Grade C"]
	"Node for Grade C evidence" [label="Body of evidence strength\n\nBody of evidence strength can impact the confidence in a recommendation and can also determine the best course of action for a patient based on their individual circumstances. Grade A indicates a balanced benefit and risk/burden, Grade B indicates uncertainty, and Grade C indicates that better evidence is likely to change confidence."]
	"Node for Grade C evidence" -> A [label="Grade A"]
	"Node for Grade C evidence" -> B [label="Grade B"]
	"Node for Grade C evidence" -> C [label="Grade C"]
	node_1 [label="Visceral metastases or bone metastases\n\nThe location of metastases is strongly associated with risk of mortality in prostate cancer patients. Visceral metastases have the highest risk, followed by bone metastases. This information should be taken into consideration when evaluating the patient's overall health and potential treatment options."]
	node_1 -> A [label="High risk of mortality"]
	node_1 -> B [label="Low risk of mortality"]
	node_2 [label="Confidence in the effect estimate\n\nThe AUA nomenclature system explicitly links statement type to body of evidence strength, level of certainty, magnitude of benefit or risk/burdens, and the Panelâ€™s judgment regarding the balance between benefits and risks/burdens (Table 3). Strong Recommendations are directive statements that an action should (benefits outweigh risks/burdens) or should not (risks/burdens outweigh benefits) be undertaken because net benefit or net harm is substantial. Moderate Recommendations are directive statements that an action should (benefits outweigh risks/burdens) or should not (risks/burdens outweigh benefits) be undertaken because net benefit or net harm is moderate. Conditional Recommendations are non-directive statements used when the evidence."]
	node_2 -> 1 [label="Very little confidence in the effect"]
	node_2 -> 2 [label="The true effect is likely to be substantially different from the estimate of effect"]
	node_3 [label="Germline and somatic genetic testing\n\nIn patients with mCRPC, clinicians should offer germline (if not already performed) and somatic genetic testing to identify DNA repair deficiency, MSI status, tumor mutational burden, and other potential mutations that may inform prognosis and familial cancer risk as well as direct potential targeted therapies."]
	node_3 -> "DDR node" [label="DNA repair deficiency"]
	node_3 -> "MSI node" [label="MSI status"]
	node_3 -> "TMB node" [label="Tumor mutational burden"]
	node_3 -> "Other mutations node" [label="Other potential mutations"]
	"Node ID: Tissue Diagnosis" [label="Tissue diagnosis from primary tumor or site of metastases\n\nRecommendation to obtain a tissue diagnosis from the primary tumor or site of metastases, if clinically feasible. This is important for accurate diagnosis and treatment planning. A multidisciplinary approach should be taken when available for patient care. Clinicians should discuss treatment options with advanced prostate cancer patients based on their life expectancy, comorbidities, preferences, and tumor characteristics."]
	"Node ID":" Tissue Diagnosis" -> "Unique identifier for treatment options node" [label="Positive diagnosis"]
	"Node ID":" Tissue Diagnosis" -> "Unique identifier for additional testing node" [label="Negative diagnosis"]
	"Unique identifier for next node" [label="Biochemical recurrence after prostatectomy\n\nAfter a prostatectomy, patients may experience biochemical recurrence, indicated by rising levels of prostate-specific antigen (PSA). This node checks for biochemical recurrence and the possible outcomes are a positive or negative result on 18F-fluciclovine PET-CT. A positive result may indicate the presence of recurrent prostate cancer, while a negative result may warrant further testing or observation."]
	"Unique identifier for next node" -> "Node 1" [label="Positive result on 18F-fluciclovine PET-CT"]
	"Unique identifier for next node" -> "Node 2" [label="Negative result on 18F-fluciclovine PET-CT"]
	"Node A" [label="Prostate cancer\n\nThe patient should be evaluated for prostate cancer based on the AUA's classification of evidence strength. Grade A evidence indicates well-conducted and highly-generalizable RCTs or exceptionally strong observational studies with consistent findings."]
	"Node A" -> 12345 [label="Grade A evidence"]
	"Node A" -> 67890 [label="Grade B evidence"]
	"Node A" -> 54321 [label="Grade C evidence"]
	"Node C" [label="DNA repair gene aberrations\n\nChecking for DNA repair gene aberrations is an important step in diagnosing metastatic castration-resistant prostate cancer. Patients who test positive for these aberrations may benefit from treatment with olaparib, as shown in the TOPARP-B trial. This is because these patients have a higher likelihood of responding to olaparib, a PARP inhibitor that targets DNA repair deficiencies. On the other hand, patients who test negative for DNA repair gene aberrations may not benefit from olaparib and other treatment options should be considered."]
	"Node C" -> "Node 1" [label="Positive for DNA repair gene aberrations"]
	"Node C" -> "Node 2" [label="Negative for DNA repair gene aberrations"]
	"Clinical trial options node" [label="Patient eligibility for clinical trial\n\nPatients should be evaluated for eligibility for clinical trials as part of the shared decision-making process. Eligibility criteria may vary based on the specific trial, but generally includes factors such as diagnosis, stage of disease, and overall health status. Patients who are eligible for clinical trials should be informed of their options and provided with information on how to find relevant trials."]
	"Clinical trial options node" -> node_2 [label="Eligible for clinical trial"]
	"Clinical trial options node" -> node_3 [label="Not eligible for clinical trial"]
	"Treatment options node" [label="Eligibility for clinical trial participation\n\nIn appropriate patients, clinical trial options should be considered and discussed with patients as part of the shared decision-making process. Clinical trials are listed by diagnosis and stage on the Clinicaltrials.gov website."]
	"Treatment options node" -> node_2 [label="Eligible for clinical trial"]
	"Treatment options node" -> node_3 [label="Not eligible for clinical trial"]
	"Advanced Prostate Cancer Node" [label="PSA recurrence\n\nGuideline for advanced prostate cancer, including disease stages from PSA recurrence to metastatic disease."]
	"Advanced Prostate Cancer Node" -> "Node 2" [label="Exhaustion of local treatment options"]
	2 [label="Level of microsatellite instability\n\nA high level of microsatellite instability has been linked to certain types of tumors and can be an indicator of a DNA-repair defect. It may be useful to test for this in patients with metastatic prostate cancer."]
	2 -> "Node 1" [label=High]
	2 -> "Node 2" [label=Low]
	"TMB node" [label="Detection of metastatic lesions\n\nAdvanced imaging tests may enhance detection of metastatic lesions, but the impact on patients and OS has not been fully demonstrated. It is still unclear what may be gained by the early detection of recurrent disease."]
	"TMB node" -> "Advanced imaging tests" [label="Enhanced detection of metastatic lesions"]
	"TMB node" -> "Unclear benefit of early detection" [label="No impact on patients or OS"]
	"Other mutations node" [label="Presence of inherited DNA repair mutations\n\nIn a population of men with metastatic prostate cancer, the prevalence of inherited DNA repair mutations was found to be 11.8%. These mutations may have implications for clinical trial eligibility and therapeutics selection, and therefore should be considered in the diagnosis and treatment of advanced prostate cancer."]
	"Other mutations node" -> "Node for genetic counseling and discussion of implications" [label="Positive for DNA repair mutations"]
	"Other mutations node" -> "Node for further testing or evaluation" [label="Negative for DNA repair mutations"]
	"Unique identifier for treatment options node" [label="Patient's stage and diagnosis\n\nIn appropriate patients, clinical trial options should be considered and discussed as part of shared decision-making process. Institutional Review Boards approve all clinical trials and patient consent forms, and patients must sign consent for trial participation. All clinical trials have specified aim(s) and predetermined statistical plan."]
	"Unique identifier for treatment options node" -> "Clinical trial website" [label="Clinical trial options"]
	"Unique identifier for treatment options node" -> "Standard therapy recommendations" [label="Standard therapy options"]
	"Unique identifier for additional testing node" [label="Advanced imaging tests\n\nAdvanced imaging tests may enhance detection of metastatic lesions, but the impact on patients and OS is yet to be fully demonstrated. It is still unclear what may be gained by the early detection of recurrent disease. In instances of planned salvage radiation therapy or salvage lymphadenectomy, the treatment templates may be adjusted as a result of novel imaging findings. In addition, oligometastatic disease may be identified and such patients may be offered enrollment in clinical trials. While such approaches may be intuitively appealing, there is limited evidence suggesting benefit in terms of a delay in disease progression (ORIOLE) or improvement in OS (SABR-COMET). There is still limited evidence that metastasis-directed therapy (MDT) confers a survival benefit."]
	"Unique identifier for additional testing node" -> "Node-2" [label="Enhanced detection of metastatic lesions"]
	"Unique identifier for additional testing node" -> "Node-3" [label="No significant impact on patients or OS"]
	12345 [label="Prostate specific antigen (PSA) levels\n\nPSA levels are often used as a screening tool for prostate cancer. Normal levels are below 4 ng/mL, but levels between 4 - 10 ng/mL may indicate the presence of cancer. Levels above 10 ng/mL are considered high and may require further testing."]
	12345 -> "Node 1" [label="PSA levels below 4 ng/mL"]
	12345 -> "Node 2" [label="PSA levels between 4 - 10 ng/mL"]
	12345 -> "Node 3" [label="PSA levels above 10 ng/mL"]
	54321 [label="Advanced Prostate Cancer\n\nAdvanced prostate cancer is a disease that has spread outside of the prostate to other parts of the body. This can include the bones, lymph nodes, or other organs. Treatment options may include surgery, radiation therapy, hormone therapy, chemotherapy, or immunotherapy. Alternatively, a patient may choose to be monitored and observed for changes in their condition."]
	54321 -> node_1 [label="Treatment options"]
	54321 -> node_2 [label="Monitoring and observation"]
	"Advanced imaging tests" [label="PSA recurrence after failure of local therapy\n\nIn patients with PSA recurrence after failure of local therapy who are at higher risk for the development of metastases (e.g., PSADT <12 months), clinicians should perform periodic staging evaluations consisting of cross-sectional imaging (CT, MRI) and technetium bone scan, and/or preferably PSMA PET imaging. (Clinical Principle)"]
	"Advanced imaging tests" -> "Node for periodic staging evaluations" [label="Higher risk for development of metastases (e.g., PSADT <12 months)"]
	"Node for genetic counseling and discussion of implications" [label="Advanced Prostate Cancer\n\nDiscussion of Genetic Information Nondiscrimination Act (GINA) and possible impact of test results on insurance. Potential role of cascade testing for family members if mutation identified. Post-test counseling necessary with genetic counselor."]
	"Node for genetic counseling and discussion of implications" -> "Counseling Node" [label="Test results positive"]
	"Node for genetic counseling and discussion of implications" -> "Treatment Node" [label="Test results negative"]
	"Node for further testing or evaluation" [label="Suspicion of advanced prostate cancer and no prior histologic confirmation\n\nIn patients with signs and symptoms suggestive of advanced prostate cancer, biopsy should be performed for histologic confirmation. This will help guide subsequent treatment based on the histologic and molecular features of the malignancy."]
	"Node for further testing or evaluation" -> "Node for biopsy" [label="Obtain tissue diagnosis from primary tumor or site of metastases"]
	"Clinical trial website" [label="Diagnosis and stage\n\nIn appropriate patients, clinical trial options should be considered and discussed as part of the shared decision-making process. Clinical trials are listed by diagnosis and stage on the Clinicaltrials.gov website. The systematic review utilized to inform this guideline was conducted by an independent methodological consultant."]
	"Clinical trial website" -> unique_identifier_1 [label="Appropriate patients for clinical trial"]
	"Clinical trial website" -> unique_identifier_2 [label="Not appropriate for clinical trial"]
	"Standard therapy recommendations" [label="PSA levels\n\nProstate-specific antigen (PSA) levels are used to screen for prostate cancer. Normal range is typically below 4 ng/mL. Elevated levels may indicate the presence of prostate cancer, but further testing is needed for a confirmed diagnosis."]
	"Standard therapy recommendations" -> "Node 2" [label="Normal range"]
	"Standard therapy recommendations" -> "Node 3" [label=Elevated]
	"Node-2" [label="Presence of DNA repair gene aberrations\n\nPatients with metastatic castration-resistant prostate cancer may have DNA repair gene aberrations which can affect treatment outcomes. This node checks for the presence of these aberrations."]
	"Node-2" -> "Node 2" [label="Positive for DNA repair gene aberrations"]
	"Node-2" -> "Node 3" [label="Negative for DNA repair gene aberrations"]
	"Node-3" [label="DNA repair gene aberrations\n\nThe presence of DNA repair gene aberrations in patients with metastatic castration-resistant prostate cancer has been linked to sensitivity to the PARP inhibitor olaparib. This node checks for the presence of these aberrations and guides the next steps accordingly."]
	"Node-3" -> node_1 [label="Positive for DNA repair gene aberrations"]
	"Node-3" -> node_2 [label="Negative for DNA repair gene aberrations"]
	"Node 3" [label="Presence of DNA repair gene aberrations\n\nA genetic test should be performed to check for the presence of DNA repair gene aberrations, which have been linked to increased risk of prostate cancer. This test can help identify patients who may benefit from targeted treatments, such as olaparib. This should be considered in patients with metastatic castration-resistant prostate cancer, as shown in the TOPARP-B trial."]
	"Node 3" -> "Node 1" [label="Positive for DNA repair gene aberrations"]
	"Node 3" -> "Node 2" [label="Negative for DNA repair gene aberrations"]
	"Node for periodic staging evaluations" [label="PSA levels\n\nCheck PSA levels every 3-6 months for monitoring. PSA alone is not completely predictive of cancer progression. Symptom assessment is important in poorly differentiated, ductal, and neuroendocrine tumors as well as mCRPC. Periodic imaging may be necessary to assess disease stability."]
	"Node for periodic staging evaluations" -> node_1 [label="Stable PSA levels"]
	"Node for periodic staging evaluations" -> node_2 [label="Elevated PSA levels"]
	"Counseling Node" [label="Suspicion of advanced prostate cancer\n\nIn patients with suspicion of advanced prostate cancer and no prior histologic confirmation, clinicians should obtain tissue diagnosis from the primary tumor or site of metastases when clinically feasible. Patients with clinical signs and symptoms suggestive of advanced prostate cancer should undergo a biopsy to obtain histologic confirmation at the time of diagnosis and at later dates, if needed. While biopsy of the metastatic deposit may be optimal, biopsy of the primary tumor may be all that is available. Although the clinical picture is often consistent with the diagnosis, subsequent treatment may strongly depend on histologic and molecular features of the malignancy."]
	"Counseling Node" -> "Node for biopsy" [label="Obtain tissue diagnosis from primary tumor or site of metastases"]
	"Treatment Node" [label="Presence of metastasis\n\nIf a patient is diagnosed with metastasis, the next step is to determine the appropriate treatment. MDT is a treatment option that utilizes radiation, surgery, or ablative technologies to target the metastatic sites. This approach has shown promise in delaying the need for systemic treatment. Alternatively, if the metastasis is widespread and systemic treatment is necessary, the patient should proceed with that treatment."]
	"Treatment Node" -> "MDT node" [label="Metastasis-directed therapy (MDT)"]
	"Treatment Node" -> "Systemic treatment node" [label="Proceed with systemic treatment"]
	"Node for biopsy" [label="Suspicion of advanced prostate cancer and no prior histologic confirmation\n\nIn patients with suspicion of advanced prostate cancer, obtaining tissue diagnosis from primary tumor or site of metastases is recommended when clinically feasible. This will help determine appropriate treatment based on histologic and molecular features of the malignancy."]
	"Node for biopsy" -> "Node identifier for obtaining tissue diagnosis" [label="Obtain tissue diagnosis from primary tumor or site of metastases"]
	unique_identifier_1 [label="ASTRO\n\nASTRO is a medical acronym for American Society for Radiation Oncology. It is a condition or symptom to check for when evaluating a patient for potential radiation therapy. In this case, the node refers to potential conflicts of interest that may arise when treating a patient with ASTRO."]
	unique_identifier_1 -> "Bristol-Myers Squibb" [label="Adam Kibel"]
	unique_identifier_1 -> 2023 [label="Conflict of Interest Disclosure"]
	unique_identifier_2 [label="ASTRO\n\nASTRO is a medical condition related to the prostate. It is important to consult with trusted medical professionals such as Adam Kibel, Bristol-Myers Squibb, and Advantagene for proper diagnosis and treatment."]
	unique_identifier_2 -> 1 [label="Consult with Adam Kibel"]
	unique_identifier_2 -> 2 [label="Consult with Bristol-Myers Squibb"]
	unique_identifier_2 -> 3 [label="Consult with Advantagene"]
	"Systemic treatment node" [label="Advanced Prostate Cancer\n\nGiven the dramatic increase in available therapies for advanced prostate cancer over the past ten years, there is a renewed urgency to identify predictive biomarkers that can guide treatment selection. Currently, the most promising markers are those associated with clinical interventions."]
	"Systemic treatment node" -> "Biomarkers and Other Systemic Therapies" [label="Identification of germline or somatic alterations within DDR genes (e.g., BRCA1, BRCA2, and ATM)"]
	"Systemic treatment node" -> "Biomarkers and Other Systemic Therapies" [label="Identification of MSI-H status"]
	"Node identifier for obtaining tissue diagnosis" [label="Suspicion of advanced prostate cancer and no prior histologic confirmation\n\nPatients with clinical signs and symptoms suggestive of advanced prostate cancer should undergo a biopsy to obtain histologic confirmation at the time of diagnosis and at later dates, if needed. While biopsy of the metastatic deposit may be optimal, biopsy of the primary tumor may be all that is available. Although the clinical picture is often consistent with the diagnosis, subsequent treatment may strongly depend on histologic and molecular features of the malignancy."]
	"Node identifier for obtaining tissue diagnosis" -> "Node for biopsy" [label="Obtain tissue diagnosis from primary tumor or site of metastases"]
	2023 [label="PSA level above normal\n\nIf a patient presents with a PSA level above the normal range, further testing should be considered to rule out prostate cancer. This could include a digital rectal exam, biopsy, or imaging studies such as an MRI or CT scan. It is important to note that other conditions such as prostatitis or benign prostatic hyperplasia (BPH) can also cause elevated PSA levels. Therefore, a thorough evaluation should be done to determine the cause of the elevated PSA before making a diagnosis of prostate cancer."]
	2023 -> node_id_1 [label="Further testing needed"]
	2023 -> node_id_2 [label="No further testing needed"]
	3 [label="Prostate cancer\n\nBased on evidence from well-conducted and highly-generalizable RCTs or exceptionally strong observational studies with consistent findings, the patient is categorized as having low or very low risk for prostate cancer. Additional information is needed to determine the appropriate next steps."]
	3 -> "Node 2" [label="Advanced prostate cancer"]
	3 -> "Node 3" [label="Localized prostate cancer"]
	"Biomarkers and Other Systemic Therapies" [label="Identification of germline or somatic alterations within DDR genes\n\nCurrently, the most promising markers are those associated with clinical interventions such as identification of germline or somatic alterations within DDR genes (e.g., BRCA1, BRCA2, and ATM) providing evidence for PARP inhibitor use and MSI-H status"]
	"Biomarkers and Other Systemic Therapies" -> "Node for PARP inhibitor use" [label="PARP inhibitor use"]
	"Biomarkers and Other Systemic Therapies" -> "Node for MSI-H status" [label="MSI-H status"]
	node_id_1 [label="Biochemical recurrence after prostatectomy\n\nPossible outcome for patients with biochemical recurrence after prostatectomy, based on results from the CONDOR phase III, multicenter study. Positive 18F-DCFPyL-PET/CT result may indicate the presence of recurrent prostate cancer, while a negative result may suggest a lower likelihood of recurrence."]
	node_id_1 -> "Node 1" [label="Positive 18F-DCFPyL-PET/CT result"]
	node_id_1 -> "Node 2" [label="Negative 18F-DCFPyL-PET/CT result"]
	"Node for PARP inhibitor use" [label="Pathogenic germline BRCA2 variants\n\nIn a retrospective analysis of a single-institution cohort of men with mCRPC, pathogenic germline BRCA2 variants were noted in 8 of 141 participants. Six of eight (75%) of those men experience PSA decline >50% within 12 weeks compared to 23 of 133 (17%) of non-carriers (absolute difference =58%; 95% CI: 27% to 88%; P<0.001)."]
	"Node for PARP inhibitor use" -> "Node ID" [label="PSA decline >50% within 12 weeks"]
	"Node ID" [label="Presence of DNA repair gene aberrations\n\nThe presence of DNA repair gene aberrations can indicate a higher risk for developing metastatic castration-resistant prostate cancer (mCRPC). These aberrations can be detected through genetic testing and may influence treatment options and outcomes."]
	"Node ID" -> "Node 1" [label="Positive for DNA repair gene aberrations"]
	"Node ID" -> "Node 2" [label="Negative for DNA repair gene aberrations"]
}
